A Neuroimmune Modulator for Alcohol Use Disorder: A Randomized Clinical Trial.

ABSTRACT:

Importance

The neuroimmune system represents a promising target for novel medications for alcohol use disorder (AUD). Ibudilast is a neuroimmune modulator which selectively inhibits phosphodiesterases (PDE) 3, PDE4, PDE10, and PDE11, and macrophage migration inhibitory factor (MIF).

Objective

To test the efficacy of ibudilast for AUD compared with placebo.

Design, setting, and participants

This randomized clinical trial was a double-masked, phase 2 trial conducted at an academic research center between October 2018 and April 2023. Eligible participants were adults seeking treatment for moderate or severe AUD. After completing the 12-week treatment period, participants were followed up for an additional 4 weeks.

Interventions

Ibudilast taken twice daily in 50 mg

SUBMITTER: Ray LA 

PROVIDER: S-EPMC12044506 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature